Published in J Biol Chem on August 05, 1991
Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci (1998) 2.52
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J (2000) 1.79
Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. EMBO J (2003) 1.60
Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest (1996) 1.49
Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev Cell (2008) 1.24
Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J (1998) 1.10
LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity. J Leukoc Biol (2010) 1.03
A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable. EMBO J (1991) 1.00
Glycoproteomic analysis of glioblastoma stem cell differentiation. J Proteome Res (2010) 1.00
Lysosomal multienzyme complex: pros and cons of working together. Cell Mol Life Sci (2013) 0.99
The blood-epididymis barrier and inflammation. Spermatogenesis (2014) 0.94
Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc Natl Acad Sci U S A (1998) 0.93
Galactosialidosis: review and analysis of CTSA gene mutations. Orphanet J Rare Dis (2013) 0.90
Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis. Mol Ther (2011) 0.88
Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex. PLoS One (2012) 0.87
Early proteolytic cleavage with loss of a C-terminal fragment underlies altered processing of the beta-galactosidase precursor in galactosialidosis. Biochem J (1996) 0.86
Proteomic analysis and identification of cellular interactors of the giant ubiquitin ligase HERC2. J Proteome Res (2014) 0.85
The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis. Proc Natl Acad Sci U S A (1998) 0.84
Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation. Biochem J (1998) 0.84
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta (2013) 0.83
Proteomic analysis of the inhibitory effect of epigallocatechin gallate on lipid accumulation in human HepG2 cells. Proteome Sci (2013) 0.76
Mice with Catalytically Inactive Cathepsin A Display Neurobehavioral Alterations. Behav Neurol (2017) 0.75
Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917. Pharmacol Res Perspect (2015) 0.75
Proteolytic activation of human cathepsin A. J Biol Chem (2014) 0.75
Galactosialidosis: historic aspects and overview of investigated and emerging treatment options. Expert Opin Orphan Drugs (2016) 0.75
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr Biol (1997) 2.99
Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein. J Biol Chem (1989) 2.91
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron (2005) 2.82
Germline mosaicism and Duchenne muscular dystrophy mutations. Nature (1987) 2.56
Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell (1997) 2.38
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature (1993) 2.36
Mammalian Golgi-associated Bicaudal-D2 functions in the dynein-dynactin pathway by interacting with these complexes. EMBO J (2001) 2.34
Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet (1999) 2.32
FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet (1999) 2.23
Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations. J Med Genet (1989) 2.11
Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature (1992) 2.04
Vesicular stomatitis virus glycoprotein, albumin, and transferrin are transported to the cell surface via the same Golgi vesicles. J Cell Biol (1983) 1.94
A mouse model for the cystic fibrosis delta F508 mutation. EMBO J (1995) 1.82
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 1.82
Association of alpha- and beta-subunits during the biosynthesis of beta-hexosaminidase in cultured human fibroblasts. J Biol Chem (1984) 1.75
Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet (1997) 1.74
Expression of cDNA encoding the human "protective protein" associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases. Cell (1988) 1.73
Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res (2000) 1.73
HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet (2003) 1.69
Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet (1995) 1.63
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Characterization and localization of the Huntington disease gene product. Hum Mol Genet (1993) 1.60
Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain (2001) 1.59
DNA probe analysis for carrier detection and prenatal diagnosis of Duchenne muscular dystrophy: a standard diagnostic procedure. J Med Genet (1986) 1.55
L1 knockout mice show dilated ventricles, vermis hypoplasia and impaired exploration patterns. Hum Mol Genet (1998) 1.54
Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta (2006) 1.53
A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. Mol Cell (1998) 1.52
Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet (2001) 1.51
Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis. Hum Mol Genet (1997) 1.49
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol (2012) 1.47
Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res (2006) 1.47
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest (1987) 1.45
Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev (1996) 1.39
Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet (2001) 1.38
Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet (2005) 1.38
The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet (2009) 1.37
Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev (1995) 1.37
Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet (1999) 1.35
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis (2005) 1.34
In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet (1998) 1.34
Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN. Oncogene (1996) 1.34
Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet (2007) 1.32
Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology (2008) 1.31
Transport and topology of galactosyltransferase in endomembranes of HeLa cells. J Cell Biol (1983) 1.26
Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol (2000) 1.25
Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet (1997) 1.24
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J (1990) 1.24
Genetic heterogeneity in human neuraminidase deficiency. Nature (1980) 1.16
New treatment modalities in advanced thyroid cancer. Ann Oncol (2011) 1.14
The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet (1994) 1.14
The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer (2001) 1.13
Single nucleotide polymorphism array analysis of chromosomal instability patterns discriminates rectal adenomas from carcinomas. J Pathol (2007) 1.13
Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet (2000) 1.13
Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency. J Biol Chem (1984) 1.12
FMR1 premutation allele (CGG)81 is stable in mice. Eur J Hum Genet (1998) 1.11
Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics (1999) 1.11
Expression of the ubiquitin-conjugating DNA repair enzymes HHR6A and B suggests a role in spermatogenesis and chromatin modification. Dev Biol (1996) 1.11
Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family. J Med Genet (1996) 1.10
Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J (1998) 1.10
Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Structure (1995) 1.09
Mouse "protective protein". cDNA cloning, sequence comparison, and expression. J Biol Chem (1990) 1.09
Workshop on inborn errors of metabolism. Prog Clin Biol Res (1982) 1.09
The human beta-globin locus control region confers an early embryonic erythroid-specific expression pattern to a basic promoter driving the bacterial lacZ gene. Development (1996) 1.09
The level of the tissue-specific factor GATA-1 affects the cell-cycle machinery. Genes Funct (1997) 1.09
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother (2004) 1.08
The fragile X phenotype in a mosaic male with a deletion showing expression of the FMR1 protein in 28% of the cells. Am J Med Genet (1996) 1.04
Prenatal diagnosis of fragile X syndrome. Lancet (1996) 1.03
A point mutation in the neu-1 locus causes the neuraminidase defect in the SM/J mouse. Hum Mol Genet (1998) 1.02
Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res (2005) 1.02
Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain (2005) 1.01
Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet (1996) 1.01
Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest (2001) 1.01
A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable. EMBO J (1991) 1.00
Identification and in vitro reconstitution of lysosomal neuraminidase from human placenta. J Biol Chem (1989) 0.99
Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients. J Neurol (2009) 0.99
Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest (1991) 0.99
Fragile X syndrome at the turn of the century. Mol Med Today (2000) 0.99
Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme. J Biol Chem (2000) 0.98
Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers (2004) 0.98
Lysosomal neuraminidase. Catalytic activation in insect cells is controlled by the protective protein/cathepsin A. J Biol Chem (2000) 0.97
alpha-N-acetylgalactosaminidase deficiency, a new lysosomal storage disorder. J Inherit Metab Dis (1988) 0.97
Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene (1991) 0.96
The subcellular localization of soluble and membrane-bound lysosomal enzymes in I-cell fibroblasts: a comparative immunocytochemical study. Eur J Cell Biol (1985) 0.95
Juvenile hyaline fibromatosis: clinical heterogeneity in three patients. Dermatology (1999) 0.95
The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav (2012) 0.95
Human lysosomal protective protein. Glycosylation, intracellular transport, and association with beta-galactosidase in the endoplasmic reticulum. J Biol Chem (1992) 0.93